Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.37
+0.06000.95%
Post-market: 6.370.00000.00%16:42 EDT
Volume:1.11M
Turnover:7.16M
Market Cap:514.41M
PE:-3.15
High:6.60
Open:6.47
Low:6.35
Close:6.31
Loading ...

Kura Oncology Inc: $455.3 Mln in Cash, Cash Equivalents and Investments Provide Runway Into 2027

THOMSON REUTERS
·
08 Nov 2024

Kura Oncology Reports Third Quarter 2024 Financial Results

GlobeNewswire
·
08 Nov 2024

Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Nov 2024

Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Buy Rating for Kura Oncology Supported by Promising Ziftomenib Data and Strategic Drug Development

TIPRANKS
·
06 Nov 2024

Kura Oncology to present updated data from KOMET-007 trial

TIPRANKS
·
05 Nov 2024

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

GlobeNewswire
·
05 Nov 2024

Kura Oncology to Report Third Quarter 2024 Financial Results

GlobeNewswire
·
31 Oct 2024

UBS Initiates Kura Oncology With Buy Rating, $27 Price Target

MT Newswires Live
·
24 Oct 2024

Kura Oncology reports preclinical data on ziftomenib

TIPRANKS
·
24 Oct 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (Gist)

THOMSON REUTERS
·
24 Oct 2024

Kura Oncology Inc - Proof-of-Concept Study of Ziftomenib Plus Imatinib to Begin in 1H 2025

THOMSON REUTERS
·
24 Oct 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
24 Oct 2024

Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Oct 2024